Treating hypertension at high altitude: The quest for a magic bullet continues

European Heart Journal

Volumn 35, Issue 44, 2014, Pages 3083-3084

  Velasco, Alejandro ^a   Vongpatanasin, Wanpen ^a   Levine, Benjamin D ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; DIURETIC AGENT; GLUCOCORTICOID; NORADRENALIN; RENIN; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ALTITUDE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DIURETIC THERAPY; DRUG EFFICACY; EDITORIAL; ENVIRONMENTAL EXPOSURE; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; HYPOBARISM; HYPOXIA; NORADRENALIN BLOOD LEVEL; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PLASMA VOLUME; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; TREATMENT RESPONSE; BLOOD PRESSURE; DRUG EFFECTS; FEMALE; MALE;

ALTITUDE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; FEMALE; HUMANS; MALE;

EID: 84913603517     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu366     Document Type: Editorial

References (17)

1. LuksAM. Should travelers with hypertension adjust their medicationswhentraveling to high altitude?. High Alt Med Biol 2009;10:11-15
2. Parati G, Bilo G, Faini A, Bilo B, Revera M, Giuliano A, Lombardi C, Caldara G, Gregorini F, Styczkiewicz K, Zambon A, Piperno A, Modesti PA, Agostoni P, Mancia G. Changes in 24 h ambulatory blood pressure and effects of angiotensin II receptor blockade during acute and prolonged high-Altitude exposure: a randomized clinical trial. Eur Heart J 2014;35:3113-3121
3. Williams B, Lacourciere Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009;23:610-619
4. Maher JT, Jones LG, Hartley LH, Williams GH, Rose LI. Aldosterone dynamics during graded exercise at sea level and high altitude. J Appl Physiol 1975;39:18-22
5. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999;5:178-187
6. VongpatanasinW. Resistant hypertension: a review of diagnosis and management. JAMA 2014;311:2216-2224
7. Baggish AL,Wolfel EE, Levine BD. Cardiovascular system. In: Swenson ER, Bartsch P, eds. High Altitude:Human Adaptation to Hypoxia.NewYork: Springer; 2014. p103-140
8. Hansen J, Sander M. Sympathetic neural overactivity in healthy humans after prolonged exposure to hypobaric hypoxia. J Physiol 2003;546:921-929
9. Mazzeo RS, Carroll JD, Butterfield GE, Braun B, Rock PB, Wolfel EE, Zamudio S, Moore LG. Catecholamine responses to alpha-Adrenergic blockade during exercise in women acutely exposed to altitude. J Appl Physiol 2001;90:121-126
10. Valentini M, Revera M, Bilo G, Caldara G, Savia G, Styczkiewicz K, Parati S, Gregorini F, Faini A, Branzi G, Malfatto G, Magrì D, Agostoni P, Parati G. Effects of beta-blockade on exercise performance at high altitude: a randomized, placebocontrolled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjects. Cardiovasc Ther 2012;30:240-248
11. Zaccaria M, Rocco S, Noventa D, Varnier M, Opocher G. Sodium regulating hormones at high altitude: basal and post-exercise levels. J Clin Endocrinol Metab 1998; 83:570-574
12. Modesti PA, Vanni S, Morabito M, Modesti A, Marchetta M, Gamberi T, Sofi F, Savia G, Mancia G, Gensini GF, Parati G. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation 2006;114:1410-1416
13. Bartsch P, Shaw S, Franciolli M, Gnadinger MP, Weidmann P. Atrial natriuretic peptide in acute mountain sickness. J Appl Physiol 1988;65:1929-1937
14. Claydon VE, Norcliffe LJ, Moore JP, Rivera M, Leon-Velarde F, Appenzeller O, Hainsworth R. Orthostatic tolerance and blood volumes in Andean high altitude dwellers. Exp Physiol 2004;89:565-571
15. Gamboa A, Gamboa JL, Holmes C, Sharabi Y, Leon-Velarde F, Fischman GJ, Appenzeller O, Goldstein DS. Plasma catecholamines and blood volume in native Andeans during hypoxia and normoxia. Clin Auton Res 2006;16:40-45
16. ChenW, Liu Q,Wang H, ChenW, Johnson RJ, Dong X, Li H, Ba S, Tan J, Luo N, Liu T, He H, Yu X. Prevalence and risk factors of chronic kidney disease: a population study in the Tibetan population. Nephrol Dial Transplant 2011;26:1592-1599
17. Gao Y, Chen G, Tian H, Lin L, Lu J,Weng J, JiaW, Ji L, Xiao J, Zhou Z, Ran X, Ren Y, Chen T, Yang W; China National Diabetes and Metabolic Disorders Study Group. Prevalence of hypertension in China: a cross-sectional study. PLoS One 2013;8: e65938